TSRL, Inc. announced that in September the company was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institute of Health (NIH).

TSRL, Inc., a privately-held preclinical accelerator, has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institute of Health (NIH) for about $300,000 over 12 months.

TSRL, Inc. will continue to broaden its MAP portfolio with the development of a once-a-week patch of Trospium Chloride (TC) optimized for improved tolerance and patient outcomes in overactive bladder (OB) disease.

Ann Arbor, Michigan, September 5, 2021 – TSRL, Inc., announces its plans to develop a sHDL lead candidate for treatment of infection complications such as sepsis in collaboration with Anna Schwendeman, PhD, from University of Michigan. The company was awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of General Medical Sciences (NIGMS) of the National Institute of Health (NIH). TSRL and its collaborator, Dr. Anna Schwendeman, will receive an estimated $1.7M over the next two years to advance SPS-701 through preclinical development towards GLP toxicology testing.

TSRL, Inc. CEO, Elke Lipka, PhD, MBA, will be speaking at the in2being, LLC. MedTechCrossroads Women Who Innovate Series webinar subseries partnership with Michigan Economic Development Corporation.

TSRL, Inc., announces the continued development of microarray patch (MAP) of Zanamivir (Relenza®), an inhalation drug product licensed for the treatment and prevention of influenza A and B. TSRL has exclusively licensed the MAP technology for its flu patch from Queen’s University Belfast, Northern Ireland, UK.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company and TSRL, Inc. (“TSRL”), a company focused on developing microneedle patches for the delivery of antivirals for the treatment of influenza, are pleased to announce that PharmaTher and TSRL (collectively the “Companies”) entered into a Co-Development Agreement to jointly develop a microneedle array patch with the aim to control the manufacturing and supply of microneedle patches for the Companies respective clinical and commercial drug programs.

TSRL, Inc., announces the continued preclinical development of a transdermal delivery system of zanamivir (Relenza®), a product licensed for the treatment and prevention of the flu.

TSRL, Inc., announces the continued development of a transdermal delivery system of zanamivir (Relenza®), an inhalation drug product licensed for the treatment and prevention of influenza A & B.

TSRL, Inc., a preclinical accelerator, announces the appointments of Martha Farmer, PhD, and Stephen Munk, PhD to the Board of Directors, and Gregory Amidon, PhD, current board member, as Chairman. In addition, Dawn Reyna was appointed to Chief Operating Officer in January of 2019.

When: Tuesday, November 12
8:00 am - 7:00 pm
Where: Kensington Court Hotel
3500 State St
Ann Arbor, Michigan 48108
United States

ANN ARBOR, MICHIGAN, August 10th, 2017—TSRL, Inc., a privately-held preclinical accelerator, announced today that the company was awarded a Phase I Small Business Technology Transfer (STTR) grant and a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID) of the National Institute of Health (NIH).

ANN ARBOR, MICHIGAN, February 17, 2017—TSRL, Inc., announced today that the company was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). TSRL will receive approximately $600,000 over the next two years for the development of a transdermal delivery system of zanamivir (GSK, Relenza®), an inhalation drug product used in the treatment of influenza A & B.

Topic: The TSRL Preclinical Accelerator: Driving Value from Lead to Clinic

Date: Friday, November 11 Time: 9  to 10 a.m.

Place: B448 Life Science Bldg

Who: Elke Lipka, MBA, PhD, President and Andrew Hertig, MBA, Business Development

Sept. 26th, 2016, Ann Arbor, Michigan: RetroSense Therapeutics, a privately-held biotechnology company developing novel gene therapies for vision restoration, announced that Allergan plc has acquired all assets related to its lead development program in an all-cash transaction. RetroSense’s RST-001 program employs a photosensitivity gene to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration. Neither of these conditions have FDA-approved treatments to improve or restore vision.

In July 2004, the Infectious Diseases Society of America (IDSA) released a report called "Bad Bugs, No Drugs." This report identified several species of antibiotic-resistant bacteria that were expected to play a lead role in the next global health crisis to come. The authors cited a high prevalence of drug-resistant infections--362,000 in the US in 2002--and lack of new antibiotics in development as warning signs. Twelve years have passed since the report published, and according to the CDC, >2 million people become infected and >23,000 die from drug-resistant infections every year. A 2009 paper by Boucher et al implicated six actors from their pathology, persistence, and presence in US hospitals: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter, Pseudomonas aeruginosa and Enterobacter. They termed them "ESKAPE" pathogens.

TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, is presenting at the 29th International Conference on Antiviral Research (ICAR) April 17th - 21st at the Hilton La Jolla Torrey Pines hotel in La Jolla, CA.

TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, is presenting at the 2015 AAPS Annual Meeting and Exposition, October 25-29, at the Orange County Convention Center in Orlando Florida.

TSRL Inc., a preclinical accelerator developing novel anti-infective therapeutics in areas of high unmet medical need, has presented on various topics at the Cutting Edge/Drug Discovery & Development in Michigan Symposium September 9th and 10th.

Members of our team at TSRL, Inc. visited the Foundations Preschool of Washtenaw County (http://www.foundations-preschool.org/) last Friday for our annual Day of Caring.

TSRL Inc., a pharmaceutical company developing novel anti-infective therapeutics in areas of high unmet medical need, is pleased to announce that Elke Lipka, PhD, MBA, has presented at the 28th International Conference on Antiviral Research (ICAR) in Rome, Italy.